EPEmilio D. Poggio

Emilio D. Poggio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emilio D. Poggio has a total of 687 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation

    by Jeffrey A. Klein, David Taber, David Wojciechowski, Didier A. Mandelbrot, Renata Glehn-Ponsirenas, Oyedolamu Olaitan, Pranjal Jain, James Lu, Martina M. McGrath, Mohanram Narayanan, et al.

    Key Points: We assessed whether an initial donor-derived cell-free DNA elevation during routine surveillance was associated with allograft dysfunction and loss in kidney transplant recipients. Intermediate and high donor-derived cell-free DNA states were independently associated with 3.7-fold and 6.4-fold higher risks of allograft loss, respectively. Persistently low donor-derived cell-free DNA levels were associated with low rates of rejection and allograft loss, identifying a low-risk population. Background: Although donor-derived cell-free DNA (dd-cfDNA) correlates with histologic rejection and injury severity, its association with long-term graft outcomes has yet to be well established in kidney transplant recipients. We hypothesize that among patients monitored with dd-cfDNA, an initial elevation may be associated with subsequent allograft dysfunction and loss. Methods: The Kidney Allograft Outcomes AlloSure Registry is a prospective, multicenter cohort of 1743 adult kidney transplant recipients from 56 US centers; this analysis included 1258 patients who initiated dd-cfDNA surveillance 15–60 days post-transplant with up to 3-year follow-up. A multistate model was applied to characterize transitions from a low dd-cfDNA state (no elevations) to intermediate (0.5%–1.0% with ≥61% relative change value) or high (≥1.0%) dd-cfDNA states, and their unadjusted and covariate-adjusted associations with allograft loss or all-cause death were quantified using hazard regression models. Results: Within 3 years, 36% of patients transitioned to an elevated dd-cfDNA state (intermediate n =216; high n =233). Allograft dysfunction by 36 months occurred significantly more often in patients with dd-cfDNA elevations despite preserved allograft function at the time of elevation (eGFR ≥60 ml/min per 1.73 m 2 in 42% of intermediate and 33% of high), consistent with subclinical injury. Transitions from low to elevated dd-cfDNA states were strongly associated with subsequent allograft loss (adjusted hazard ratios, 3.70 [95% confidence interval [CI], 1.38 to 9.90] for intermediate; 6.36 [95% CI, 2.80 to 14.42] for high), while mortality did not differ by dd-cfDNA state. Conclusions: Initial dd-cfDNA elevations exceeding established thresholds were independently associated with higher risks of allograft dysfunction and loss across both elevation categories, whereas patients who remained in the low dd-cfDNA state experienced favorable outcomes.

  • Open Access

    A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection

    by Beatrice P. Concepcion, Oriol Bestard, Milagros Samaniego-Picota, Rohini Prashar, M. Javeed Ansari, Giorgia Comai, Elisa Gessaroli, Lionel Rostaing, Federico Alberici, Roslyn B. Mannon, et al.

    Key Points: Pretransplant early acute rejection risk stratification offers a novel approach to personalized immunosuppression management in patients who received a kidney transplant. Stratifying immunologic risk independent of donor characteristics may help guide immunosuppression management in patients who received a kidney transplant. The pretransplant risk assessment gene set reflects metabolic and immune pathways involved in T-cell– and antibody-mediated mechanisms of transplant rejection. Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection (EAR). We developed and validated a next-generation sequencing assay targeting the pretransplant immunologic profile to predict EAR following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected before transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pretransplant risk assessment (PTRA) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict EAR risk was clinically validated using 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high risk and 91 (75%) as low risk. There were nine EAR events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for EAR at 60 days post-transplant yielded an area under the curve of 0.78 (95% confidence interval [CI], 64.4 to 91.5), P < 0.001. A cutoff of ≤45 was defined as low risk and >45 as high risk for EAR within 60 days post-transplant. Sensitivity was 0.67 (95% CI, 0.36 to 0.97), specificity 0.78 (95% CI, 0.70 to 0.86), positive predictive value 0.19 (95% CI, 0.05 to 0.33), and negative predictive value 0.97 (95% CI, 0.93 to 1.00). The odds ratio comparing patients identified as high versus low risk by PTRA was 7.04 (95% CI, 1.64 to 30.2), P = 0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high or low risk for EAR using a pretransplant transcriptomic profile, with implications for graft health and personalized treatment management.


  • Open Access

    Impact of older donor age in kidney transplants in a biopsy-based observational study

    by Katelynn Madill-Thomsen, Martina Mackova, Jessica Chang, Enver Akalin, Tarek Alhamad, Sanjiv Anand, Miha Arnol, Rajendra Baliga, Mirosław Banasik, Christopher Blosser, et al.

    Because older donor age is a major concern when considering kidneys for potential transplantation, we explored the actual effect of donor age on the features of kidneys that have been transplanted. We studied the correlations of donor age with molecular injury and rejection scores in 4,502 kidney transplant biopsies assessed by microarrays as well as function and postbiopsy survival. We used multivariable analyses to correct for the correlations of donor age with other predictive variables: recipient age, time of biopsy after transplant, and deceased versus living donors. Older donor age correlated with lower glomerular filtration rate (GFR) and increased acute and chronic injury transcripts but had no effect on rejection, which was anticorrelated with recipient age. Acute injury transcripts peaked immediately after transplant and regressed. Older donor age had little effect on acute molecular injury immediately after transplant but strongly increased molecular injury scores at later times, peaking about 1-year after transplant, indicating that older age does not increase molecular injury but increases failed repair after injury. As expected, older donor age correlated with increased chronic injury and lower GFR, evident from the earliest time after transplant, pretransplant aging. However, despite substantial age-related effects, the quantitative contribution of donor aging to molecular injury, function, and survival was very small.

  • Open Access

    Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

    by Christine E. Koval, Mohamed Eltemamy, Nabin K. Shrestha, Leal Herlitz, Emilio D. Poggio, Alvin C. Wee

    Background: Data demonstrates safety and short‐term success of kidney transplantation (KT) from SARS‐CoV‐2 NAT‐positive organ donors (NAT+) compared to NAT‐negative donors. However, detailed reports of longer‐term graft outcomes are limited and lack granular data on donor SARS‐CoV‐2 infection severity. Methods: We retrospectively reviewed records from 220 recipients of KT (KTRs) at our institution from February 1, 2021, to January 31, 2022. We compared 1‐ and 3‐year allograft‐specific outcomes for KTRs from NAT+ ( N = 59), CoV‐COD (COVID as cause of death) ( N = 56), and NAT‐neg ( N = 105) donors. We reviewed and compared pathology findings for allograft biopsies for all groups up to 1 year. We examined the association of eGFR at 3 years with CoV‐donor status using multivariable linear regression. Results: At 1 year, there was no difference in rejection or kidney pathologies by CoV‐donor status. At 3 years, there was no difference in patient death or graft loss by group. For subjects without graft loss, eGFR at 3 years for NAT+, CoV‐COD, and NAT‐neg donors was 54.8 (21.8), 45.6(17.9), and 48.4 (23.3) mL/min/m 2 , respectively ( p = 0.61). On multivariable analysis, there was no significant association of eGFR with CoV‐donor status. Conclusions: We found no significant difference in pathological findings or 3‐year allograft outcomes following KT from NAT‐negative, NAT+, or CoV‐COD donors. Despite modestly reduced eGFR for COV‐COD on unadjusted analysis, kidneys from donors with a spectrum of COVID severities did not experience significantly poorer allograft outcomes over 3 years. image

  • Open Access

    Association of Noninvasive Rejection Biomarkers with 10-Year Kidney Allograft Survival

    by James N. Fleming, David Taber, Raymond L. Heilman, Emilio Poggio, Christopher Marsh, Sunil Kurian, Lihui Zhao, Mulugeta Gebregziabher, Steve Kleiboeker, John J. Friedewald

    Key Points: There is an independent association between two independent noninvasive biomarkers and all-cause graft loss. Time-varying analysis demonstrated that the independent noninvasive biomarkers can provide more information than either one alone. Background: The primary objective of this analysis was to assess the association between noninvasive biomarker results within the first 2 years postkidney transplant and 10-year all-cause graft loss (ACGL). Methods: Clinical Trials in Organ Transplantation 08 (CTOT-08) study was linked with the Scientific Registry of Transplant Recipients to assess 10-year ACGL. Cox regression was used to determine the association between gene expression profile (GEP) and donor-derived cell-free DNA (dd-cfDNA) results and ACGL. A Cox regression with time-varying covariates was used to test associations with ACGL with simultaneous and repeated biomarker results. Results: The final landmarked Cox model included clinical acute rejection (adjusted hazard ratio [aHR], 2.58 [1.30 to 5.13] for one rejection; aHR, 3.41 [1.07 to 10.85] for two rejections), diabetes (aHR, 1.71 [0.99 to 2.96]), recipient age (aHR, 1.02 [1.00 to 1.04]), the highest quartile of positive GEP (aHR, 2.44 [1.45 to 4.10]), and the highest quartile of positive dd-cfDNA (aHR, 2.91 [1.77 to 4.78]). In the time-varying model, having both biomarkers positive at the same time carried the greatest association with ACGL (aHR, 4.29 [2.10 to 8.76]). Conclusions: In this multicenter, prospective analysis of GEP and dd-cfDNA on patient and graft outcomes, an independent association with long-term ACGL was demonstrated. Furthermore, a time-varying analysis demonstrated that two biomarkers with independent methodologies tested at the same time can provide more information than either one alone. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT01531257.


  • Open Access

    Biopsy and Blood Gene Expression Distinguish Injury, Subclinical and Clinical Rejection in Kidney Transplant Recipients

    by Sunil M. Kurian, Christabel N. Rebello, Sook Hyeon Park, Raymond L. Heilman, Emilio D. Poggio, Michael M. Abecassis, Christopher L. Marsh, John J. Friedewald

    Background.: Long-term outcomes in kidney transplantation remain suboptimal, with subclinical acute rejection (subAR) frequently going undetected by conventional methods. We hypothesized that subAR represents a molecular precursor to clinical acute rejection (cAR). Leveraging a large National Institutes of Health-funded cohort with matched kidney tissue and peripheral blood samples, our primary objective was to determine whether subAR and cAR share molecular patterns, establishing subAR as an early stage of cAR. As a secondary aim, we compared biopsy and blood gene expression profiles to identify unique and shared pathways and to assess their diagnostic utility. Methods.: This was a retrospective analysis of gene expression data from an observational clinical trial. We analyzed 578 blood and biopsy samples from 129 kidney transplant recipients enrolled in a multicenter observational study. Gene expression differences were analyzed using ANOVA with false discovery rate correction and molecular pathways analysis. Samples were matched and classified based on histologic findings and blood-based molecular diagnostics. Results.: Gene expression and pathway analyses revealed that subAR exhibits a molecular profile consistent with a milder form of clinical rejection in both tissue and blood. Molecular signatures distinguished immune-mediated injury from nonimmune injury. Notably, tissue gene expression profiling in cases that were misclassified by peripheral blood diagnostics were like correctly classified cases, suggesting that histology alone may not reliably define true clinical phenotypes. Conclusions.: Molecular profiling of tissue and blood reflects distinct but complementary aspects of transplant biology and confirms that subAR and cAR share overlapping molecular profiles, supporting the hypothesis that subAR represents an early stage in the progression toward clinical rejection. These findings highlight the limitations of relying solely on histological evaluation and support the use of molecular tissue profiling as an adjunct to histology, particularly in diagnostically ambiguous cases. Molecular profiling provides a supporting framework for identifying subclinical rejection and guiding personalized immunosuppression to improve long-term outcomes.

  • Open Access

    Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants

    by Luis G. Hidalgo, Katelynn S. Madill-Thomsen, Jeff Reeve, Martina Mackova, Philippe Gauthier, Zachary Demko, Adam Prewett, Michelle Lee, Tarek Alhamad, Sanjiv Anand, et al.


  • Open Access

    A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes

    by Philip F. Halloran, Jessica Chang, Martina Mackova, Katelynn S. Madill-Thomsen, Enver Akalin, Tarek Alhamad, Sanjiv Anand, Miha Arnol, Rajendra Baliga, Mirosław Banasik, et al.

    Background. Expression of acute kidney injury–associated (AKI-associated) transcripts in kidney transplants may reflect recent injury and accumulation of epithelial cells in “failed repair” states. We hypothesized that the phenomenon of failed repair could be associated with deterioration and failure in kidney transplants. Methods. We defined injury-induced transcriptome states in 4,502 kidney transplant biopsies injury-induced gene sets and classifiers previously developed in transplants. Results. In principal component analysis (PCA), PC1 correlated with both acute and chronic kidney injury and related inflammation and PC2 with time posttransplant. Positive PC3 was a dimension that correlated with epithelial remodeling pathways and anticorrelated with inflammation. Both PC1 and PC3 correlated with reduced survival, with PC1 effects strongly increasing over time whereas PC3 effects were independent of time. In this model, we studied the expression of 12 “new” gene sets annotated in single-nucleus RNA-sequencing studies of epithelial cells with failed repair in native kidneys. The new gene sets reflecting epithelial-mesenchymal transition correlated with injury PC1 and PC3, lower estimated glomerular filtration rate, higher donor age, and future failure as strongly as any gene sets previously derived in transplants and were independent of nephron segment of origin and graft rejection. Conclusion. These results suggest 2 dimensions in the kidney transplant response to injury: PC1, AKI-induced changes, failed repair, and inflammation; and PC3, a response involving epithelial remodeling without inflammation. Increasing kidney age amplifies PC1 and PC3. Trial registration. INTERCOMEX (ClinicalTrials.gov NCT01299168); Trifecta-Kidney (ClinicalTrials.gov NCT04239703). Funding. Genome Canada; Natera, Inc.; and Thermo Fisher Scientific.


  • Implementation of a Comprehensive Protocol for Enhanced Recovery After Surgery (ERAS) in Kidney Transplant Recipients Improves Patient and Graft Outcomes

    by Mohamed Eltemamy, Paul J. Oh, Hafiz Umair Siddiqui, Yi‐Chia Lin, M. Cecilia Lansang, Emilio Poggio, David Goldfarb, Venkatesh Krishnamurthi, Alvin Wee

    Background: Enhanced recovery after surgery (ERAS) protocols have gained widespread acceptance as a means to enhance surgical outcomes. However, the intricate care required for kidney transplant recipients has not yet led to the establishment of a universally recognized and dependable ERAS protocol for kidney transplantation.Objective: We devised a customized ERAS protocol to determine its effectiveness in improving surgical and postoperative outcomes among kidney transplant recipients.Design, Setting, and Participants: This was a retrospective, single‐center study performed at our tertiary care institution. Three hundred and fifty‐six patients in the conventional group (from January 1, 2015 to December 31, 2017) and 442 patients from the ERAS group (from January 1, 2018 to June 1, 2020) were compared. Patients were followed for 1 year postoperatively.Intervention: Changes were made in the preoperative, operative, postoperative, and outpatient follow‐up settings after transplantation.Outcome Measurements and Statistical Analysis: Primary endpoints were hospital length of stay (LOS) and 30‐day readmission rates. We also measured surgical outcomes, graft performance, and patient survival. Wilcoxon rank‐sum, Pearson's Chi‐squared, or Fisher's exact tests were used to compare groups.Results: Our ERAS protocol was associated with a decrease in hospital LOS from 5 to 3 days (p < 0.001) and 57.1% lower odds of hospital readmissions within 30 days compared to the conventional group (p < 0.001, 95% CI 0.26–0.7). Decreases in operative estimated blood loss, blood transfusion rates, and delayed graft function were also associated with the ERAS protocol.Conclusion: Our multi‐layered ERAS protocol is effective in improving outcomes for kidney transplant recipients. A future multi‐institutional study with healthcare savings analysis may suggest that widespread benefits are yet to be realized by the greater implementation of such enhanced recovery protocols.


  • Open Access

    Subthreshold rejection activity in many kidney transplants currently classified as having no rejection

    by Philip F. Halloran, Katelynn S. Madill-Thomsen, Georg Böhmig, Jonathan Bromberg, Klemens Budde, Meagan Barner, Martina Mackova, Jessica Chang, Gunilla Einecke, Farsad Eskandary, et al.